InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,386.00
(
0.33%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
74.85
(
1.51%
)
Bitcoin
63,628.62
(
0.48%
)
Post# of 1850
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

MinnieM

Send PM Follow Ignore
Followers 617
Posts 27445
Boards Moderated 3
Alias Born 11/16/2007

MinnieM

Re: None

Tuesday, 05/05/2020 12:38:32 AM

Tuesday, May 05, 2020 12:38:32 AM

Post# of 1850
Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19

https://investors.alnylam.com/press-release?id=24796

May 04, 2020

- Highly Potent and Broadly Cross-Reactive RNAi Therapeutic Development Candidate Selected Only Three Months After Program Initiation -

- Companies Expect to Start Human Clinical Trials at or Around Year-End 2020 –



$ALNY







To follow KarinCA, click here then click "Follow This Member" under my photo.

Be kinder than necessary, for everyone you meet is fighting some kind of battle.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up